electroCore to present at European headache meeting on non-invasive
vagus nerve stimulation therapy for cluster headache
18 September 2014
This weekend, at the European Headache and Migraine Trust
International Congress in Copenhagen (EHMTIC), electroCore will be
presenting full data on their PREVA study, a randomized,
multi-centre trial across several European countries.
The trial showed that preventative use of non-invasive vagus
nerve stimulation (nVNS) can substantially reduce the frequency of
cluster headache attacks (ie by 43.4%) versus the control group (the
current standard of care, which experienced only a 12% reduction).
Three poster presentations will provide full details of the PREVA
trial and include:
- A report on the randomized phase
- A report on the open label phase
- An analysis of quality of life impact
On Saturday evening electroCore is hosting a satellite symposium
with three eminent headache specialists:
- Professor Jean Schoen, Director of the Headache Research
Unit at the University of Liège, Belgium, who will provide an
overview of Neuromodulation and the role of non-invasive vagus
nerve (nVNS) stimulation.
- Dr Charly Gaul, Director of the Migraine and Headache Clinic
Königstein, Germany and the principle investigator of the PREVA
trial who will comprehensively explore the use of nVNS in the
prevention of cluster headache.
- Professor Stephen Silberstein, Director of the Thomas
Jefferson Headache Centre at the Thomas Jefferson University and
Hospitals Philadelphia, who will present data on nVNS in the
prevention of chronic migraine.
New Jersey based electroCore has developed non-invasive Vagus
Nerve Stimulation (nVNS) therapies, which are self-administered by
patients for the treatment of multiple conditions in neurology,
psychiatry, respiratory and other fields.